摘要
放射性碘标记间碘苄胍([*I]MIBG)在神经内分泌肿瘤和心脏病的诊断,以及神经内分泌肿瘤的治疗方面起着重要作用。高比活度无载体放射性碘标记MIBG(no-carrier-added(n.c.a.)[*I]MIBG)克服了目前商用放射性碘标记MIBG(carrier-added(c.a.)[*I]MIBG)的缺点,有利于临床使用。近20年来,无载体放射性碘标记MIBG的制备和应用研究逐渐得到重视,并取得了重要进展。本文对无载体放射性碘标记MIBG的制备方法进行了总结,对n.c.a.[*I]MIBG和c.a.[*I]MIBG诊断与治疗方面的特点进行了对比,同时介绍了其在临床研究方面的最新进展。
Radioiodinated metaiodobenzylguanidine（MIBG）is an important diagnostic agent for oncology and cardiology,or as a targeted radiotherapeutic for neuroendocrine tumors.Commercial formulations of radioiodinated MIBG（carrier-added（c.a.）[＊I]MIBG）contain large mass amount of unlabeled MIBG,which is disadvantage to diagnosis or therapy with adverse effects in patients.High specific activity no-carrier-added radioiodinated MIBG（n.c.a.[＊I]MIBG）has the advantage of lower risk of adverse effects and is more suitable for clinical diagnostic and therapy.Much importance was attached to the preparation and application of n.c.a.[＊I]MIBG,and great achievements had been made in the last 20 years.Here we considered the methods of preparation of n.c.a.[＊I]MIBG,comparison of n.c.a.[＊I]MIBG and c.a.[＊I]MIBG in diagnostic and therapy,and the clinical status of n.c.a.[＊I]MIBG.
出处
《同位素》
CAS
2017年第1期54-62,共9页
Journal of Isotopes
关键词
间碘苄胍
无载体
高比活度
诊断
放射性治疗
meta-iodobenzylguanidine
no-carrier-added
high specific activity
diagnostic
radiotherapy
